Immatics N.V.
IMTXDrugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Aug 12, 2026
9dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
IMTX Earnings Report
EPS Est: $-0.43 | FQ end 2026-06
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
IMA203 | Phase 3 | Melanoma, Cutaneous Malignant | - | - |
IMA203 Product | Phase 2 | Refractory Cancer | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Immatics N.V.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Immatics N.V.'s (IMTX) pipeline across Phase 3, Phase 2. Its lead program is IMA203 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Immatics N.V.'s next FDA catalyst?→
Immatics N.V.'s (IMTX) next tracked catalyst is a Earnings expected August 12, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track IMTX biotech catalysts?→
Add IMTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Immatics N.V.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.